sglt2 inhibition in type 1 diabetes patients | john wilding
Published 6 years ago • 820 plays • Length 3:44Download video MP4
Download video MP3
Similar videos
-
14:06
sglt2 inhibitors: the story so far | john wilding
-
1:53
sglt2 inhibition in type 1 diabetes | lori berard
-
3:38
expert commentary: the rewind trial | john wilding
-
6:58
sglt2 inhibitors in t1d: 'people are using them now'
-
3:19
expert highlights: high-performance exercise and type 1 diabetes | john wilding
-
5:50
researcher comment: declare-timi 58 | john wilding
-
18:00
dkd treatment update: sglt2 inhibitors and finerenone | ian de boer & amrit lamba
-
50:30
protocols for safe use of sglt2i and glp1ra in the hospital setting
-
59:01
initiating and managing sglt2 inhibitors in type 2 diabetes webinar
-
6:14
the daily debate - sglt-2 inhibitors and t1d
-
0:38
clinical takeaway: the carolina trial | john wilding
-
1:54
the updated diabetes uk nutrition guidelines: an obesity specialist’s view | john wilding
-
22:08
how was it for you? the experts discuss easd 2019 | john wilding, amrit lamba, and lori berard
-
10:11
diabetic retinopathy: treatment | philip burgess & john wilding
-
2:44
expert commentary: the harmony trial | john wilding
-
0:30
sglt2 inhibitors for diabetics
-
6:00
ada 2021 – surpass-3: tirzepatide versus insulin degludec in type 2 diabetes | francesco giorgino
-
8:28
sglt2 inhibitors in patients without diabetes at risk of hf
-
4:41
researcher comment: the pioneer 6 oral semaglutide cardiovascular outcomes study | mansoor husain